Form 4: Director Luke Evnin Sells Werewolf Therapeutics Shares

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 171,049 shares of common stock via a Rule 10b5-1 trading plan.

Summary

• Director Luke Evnin sold a total of 171,049 shares of Werewolf Therapeutics (HOWL) common stock between May 18 and May 20, 2026.
• The sales were executed through various investment entities managed by the director, including MPM BioVentures 2014, L.P. and MPM Oncology Innovations Fund, L.P.
• Transactions were conducted under a pre-established Rule 10b5-1 trading plan dated March 26, 2026.
• Following these transactions, the reporting person maintains a beneficial interest in 955,447 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as neutral-to-negative; while the sales were pre-planned, the consistent selling at low price points reflects a lack of upward momentum for the stock.

Positives

• The sales were executed pursuant to a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The director reduced his indirect beneficial ownership stake in the company.
• The shares were sold at prices ranging between $0.43 and $0.50, reflecting a low valuation for the company's equity.

Risks

• Continued selling pressure from major institutional insiders may negatively impact market sentiment.
• The low share price range ($0.43 $0.50) suggests potential challenges in the company's market valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling in the biotech sector is common, particularly when funds reach the end of their investment lifecycle or when pre-planned 10b5-1 programs are triggered. The low price point of these sales is consistent with broader volatility in the small-cap biotechnology space.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to ensure compliance with SEC regulations while liquidating positions.
• The sale of shares by venture capital-backed directors is typical as funds reach maturity.

Related Party Transactions

• The reporting person is a Managing Director or manager of several MPM-affiliated entities that hold the shares.

Stakeholder Impact

• Shareholders may perceive the ongoing insider selling as a lack of confidence in near-term price appreciation.

Next Steps

• Continued monitoring of Form 4 filings for further insider activity.

Key Dates

Recommendation

The filing represents routine insider selling via a pre-planned program. While the low price is concerning, it does not indicate a fundamental change in company strategy or immediate operational distress.

Keywords

Werewolf Therapeutics, HOWL, Insider Trading, Form 4, Biotech, Luke Evnin